Education
About Us
Working with TipRanks
Follow Us
Prescient Therapeutics Limited (AU:PTX)
ASX:PTX
PTX Stock Chart & Stats
AU$0.08
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.08
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.04 - AU$0.13
Previous CloseN/A
Volume766.17K
Average Volume (3M)690.15K
Market Cap
AU$68.35M
Enterprise ValueAU$61.44M
Total Cash (Recent Filing)AU$6.93M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Feb 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,051,514,500
10 Day Avg. Volume838,009
30 Day Avg. Volume690,151
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)3.11
Price to Sales (P/S)8.13
P/FCF Ratio-4.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained ~44% YoY revenue growth signals meaningful commercial or clinical progress and expanding traction for the company’s programs. Over 2–6 months this supports scaling potential and provides a base to absorb fixed R&D costs, improving odds of long‑term margin improvement if growth continues.
High Gross ProfitConsistently high gross profit indicates the core products or services have attractive unit economics. That structural margin advantage can enable operating leverage: as revenue scales, high gross margins make it easier to convert top-line growth into operating profit over time, assuming disciplined SG&A and R&D spend.
Low Financial LeverageMinimal debt reduces refinancing and interest‑rate risk and preserves strategic optionality for R&D investments or partnerships. A low leverage profile is a durable strength for a development‑stage biotech, giving management flexibility to pursue clinical programs without heavy fixed‑charge burdens.
Bears Say
Negative Free Cash FlowPersistent negative free cash flow and a recent ~25% deterioration highlight an elevated cash burn profile. Over a multi‑month horizon this increases dependence on external financing, raises dilution risk, and constrains the company’s ability to self‑fund clinical programs or scale commercialization without raising capital.
Structural Net LossesOngoing operating and net losses despite revenue growth indicate the business has not yet reached a scalable cost structure. This structural unprofitability pressures retained capital, limits free cash generation, and makes near‑term self‑sustaining operations unlikely without strategic cost reductions or new funding.
Eroding Equity And Negative ROEDeclining equity and persistently negative ROE signal capital dilution and value consumption from losses. This weakens the company’s capital base over time, making future fundraising more dilutive and reducing cushion against setbacks in clinical or commercial execution.
Prescient Therapeutics Limited News
PTX FAQ
What was Prescient Therapeutics Limited’s price range in the past 12 months?
Prescient Therapeutics Limited lowest share price was AU$0.04 and its highest was AU$0.13 in the past 12 months.
What is Prescient Therapeutics Limited’s market cap?
Prescient Therapeutics Limited’s market cap is AU$68.35M.
When is Prescient Therapeutics Limited’s upcoming earnings report date?
Prescient Therapeutics Limited’s upcoming earnings report date is Feb 20, 2026 which is in 3 days.
How were Prescient Therapeutics Limited’s earnings last quarter?
Prescient Therapeutics Limited released its earnings results on Aug 20, 2025. The company reported -AU$0.006 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.006.
Is Prescient Therapeutics Limited overvalued?
According to Wall Street analysts Prescient Therapeutics Limited’s price is currently Overvalued.
Does Prescient Therapeutics Limited pay dividends?
Prescient Therapeutics Limited does not currently pay dividends.
What is Prescient Therapeutics Limited’s EPS estimate?
Prescient Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prescient Therapeutics Limited have?
Prescient Therapeutics Limited has 1,051,514,500 shares outstanding.
What happened to Prescient Therapeutics Limited’s price movement after its last earnings report?
Prescient Therapeutics Limited reported an EPS of -AU$0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.273%.
Which hedge fund is a major shareholder of Prescient Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:PTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prescient Therapeutics Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.54%
12-Months-Change
Fundamentals
Return on Equity
-49.72%
Trailing 12-Months
Asset Growth
-28.59%
Trailing 12-Months
Company Description
Prescient Therapeutics Limited
Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. It has a strategic collaboration with The University of Texas MD Anderson Cancer Center to develop blood cancer binder for OmniCAR. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.
Technical Analysis
Cynata Therapeutics Limited
―
Starpharma Holdings Limited
―
Avecho Biotechnology Limited
―
Chimeric Therapeutics Ltd.
―
Arovella Therapeutics Limited
―
Options Prices
Currently, No data available
---